This observational study, called PiMZ Logic, is looking at people with a specific type of Alpha-1 Antitrypsin Deficiency (AATD) called PiMZ. AATD is a genetic condition that can affect your lungs and liver. The study wants to understand why some people with PiMZ AATD get worse lung disease faster than others. Researchers will look at changes in your lung density using CT scans and measure certain markers in your blood and sputum over three years. The goal is to find early signs that can predict who might get worse quickly, so doctors can eventually find ways to help prevent serious problems. You may be able to join if you are 18 or older, have PiMZ AATD, and have certain lung function test results (FEV1 < 80% predicted AND FEV1/FVC < 70%). The study is currently unclear on its recruitment status.

Study design

This is an observational study, meaning no specific intervention is being tested. It plans to enroll 80 participants.

What's involved

You would have your medical history reviewed, give blood samples, undergo spirometry (a breathing test), potentially provide sputum samples, complete questionnaires, and have chest CT scans at the beginning and again three years later.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for three years to assess changes in lung density and other markers.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.